TXG Stock — 10x Genomics, Inc.

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 4 wks

Latest filing: 10-Q

filed Aug 7, 2026

Q2 2026 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$616.91M

Trailing 12 months

Net income (TTM)

−$75.12M

Trailing 12 months

Revenue growth YoY

-12.6%

Year over year

Operating margin

-14.3%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

1.1%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+4.4%

Year over year · more shares

Price change (1Y)

+666.6%

Trailing year

Short interest

12.8%

Latest settlement · 7.1 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026

Q2 FY26

TL;DR. 10x Genomics reported Q2 revenue of $151 million (3% ex-settlement YoY) and raised full-year 2026 revenue guidance to $610–$630 million, citing extraordinary early order flow for its new Atera spatial platform that has already exceeded the company's full-year shipment target of 40 units.

Bullish

+ Raised full-year 2026 revenue guidance to $610–$630 million from $600–$625 million.
+ Gross margin expanded to 74% from 72%, and to 74% from 67% on an ex-settlement basis.
+ Total consumables revenue grew 7%, with spatial consumables up 16% and double-digit growth in single-cell reaction volumes.
+ Cash and marketable securities of $552 million, up $105 million year over year.
+ Completed acquisition of Proteintech Genomics and announced Cleveland Clinic and Lausanne University Hospital research collaborations to advance diagnostics strategy.

Bearish

− Q2 operating loss of $19.6 million vs. operating income of $30.1 million a year ago, and net loss of $17.9 million vs. net income of $34.5 million.
− Total instrument revenue declined 47%, with Chromium instruments down 46% and spatial instruments down 48% on lower unit sales.
− APAC revenue fell 19%, partly reflecting a $4 million prior-year China pull-forward.
− Academic funding environment remains tenuous, with grant dollars not yet translating into purchasing activity.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Bearish Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 15 · calm Equity put/call 0.57

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +127%

above

Price vs 50-day avg +21%

above

RSI (14) 53

neutral

MACD trend Positive

52-week position 80%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +23%

trailing

6-month return +218%

trailing

YTD return +395%

this year

Relative strength +207%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $67 › 200d $35 — 50d above 200d

Institutional flow Distributing

3 of 394 funds reported for Sep 30 · net -11.3K sh shares · +1 new

Insider flow Distributing

Net -$5.5M over 90 days · 100% sells

Short interest Rising

12.81% of float · ▲ +3.3% MoM · 7.1 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Multi-yr high

394 holders — near 3-yr high, broad support

Squeeze score 83

high risk · 0–100

Fundamentals

Excellent

Revenue growth +68%

Y/Y

Gross margin 181%

contracting

EPS growth +77%

Y/Y

Free cash flow $130.1M

Balance sheet $663.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 75%

annualized · 1-yr

Max drawdown −28%

past year

ATR 8.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 3 of last 4

Latest guidance · from the 8-K filed Aug 6, 2026

Revenue · full year 2026 Initiated $610M – $630M

prior FY $642.82M midpoint −3.6% Y/Y

Guided vs delivered · last 4 settled

Revenue full year 2024

guided $640M – $660M

guided $640M – $660M $610.79M Miss −6.0%

Revenue full year 2023

guided $610M – $625M

guided $610M – $625M $618.73M In line

Revenue full year 2022

guided $500M – $520M

guided $500M – $520M $516.41M In line

Full-year 2021 revenue full-year 2021

guided $490M – $500M

guided $490M – $500M $490.49M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

0 · 4 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+127% Bullish

Price vs 50-day avg

+21% Bullish

RSI (14)

53 Neutral

MACD trend

Positive Bullish

52-week position

80% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $67 › 200d $35 — 50d above 200d

Institutional flow Distributing

3 of 394 funds reported for Sep 30 · net -11.3K sh shares · +1 new

Insider flow Distributing

Net -$5.5M over 90 days · 100% sells

Short interest Rising

12.81% of float · ▲ +3.3% MoM · 7.1 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Multi-yr high

394 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $11 Now $81 · 80% Range high $98

vs 200-day avg +127% vs 50-day avg +21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TXG 10x Genomics, Inc. this stock	$11.17B	+394.5%	+68.1%	—	12.8%
ABT Abbott Laboratories	$174.90B	-21.7%	+5.7%	28.1	1.1%
MDT Medtronic plc	$113.38B	-9.3%	+8.4%	21.8	1.3%
SYK Stryker Corp	$104.47B	-20.8%	+11.2%	28.2	2.0%
BSX Boston Scientific Corp	$63.59B	-55.8%	+12.5%	17.8	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

395

% held: 99.2%
Reported: 3 of 394
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

318

View

Short & Settlement

Short Interest Rising

Shares short

16.7M

Days to cover: 7.1d
Change: +530.4K sh

View

Short Volume

Short vol %

46%

As of: Oct 6, 2026

Short Total

View

Fails to Deliver

FTD shares

104.6K

Value: $6.9M
As of: Sep 11, 2026

View

Off-Exchange

Off-exchange %

47.7%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$5.5M

Buyers / Sellers: 0 / 4

Buyers Sellers

View

Financials

Revenue (FY)

$642.8M

Net income (FY): $-43.5M
EPS diluted: $-0.35

View

Filings

SEC Filings

Latest

10-Q

Filed: Aug 7, 2026
This year: 9

View

Proposed Sales

Value

$3.0M

Shares: 46.4K
Filed: Sep 9, 2026

View

Earnings & Events

Webcasts

Last webcast

Aug 6, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
TXG	-10.4%	+23.0%	+218.2%	-10.7%	+394.5%
SPY	+2.0%	+1.7%	+11.3%	+2.2%	+14.3%
vs SPY	-12.4%	+21.3%	+206.9%	-12.9%	+380.3%

TXG · 10x Genomics, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance